Navigation Links
Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing
Date:11/12/2013

BURLINGTON, Mass., Nov. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions, and their use in clinical trials of drugs outside of oncology is building. The Strategic Insights report entitled Driving Drug and Diagnostic R&D: The Influence of Biomarkers Beyond Oncology, finds that through biomarkers, upcoming chronic disease drugs will target new mechanisms of action, address niche subpopulations and fill the need for safer and more effective treatments. Biomarkers, when placed at the core of R&D programs, can reveal essential information about the drugs in development and/or the target populations.

According to the report, an analysis of ongoing clinical trials using biomarkers reveals a plethora of opportunities for drug R&D in a number of non-oncology therapy areas. Collectively, there are more clinical trials and deals over the last five years involving biomarkers for non-cancer indications than those focusing solely on cancer indications. For instance, all of AbbVie's trials using biomarkers are in non-cancer areas, as are more than half of all biomarker-focused trials sponsored by Merck, Roche, GlaxoSmithKline and Pfizer. While most active clinical trials involving biomarkers are in earlier phases, biomarkers in late-phase trials support label extension or evaluate long-term safety.

The report also explores how companies are capitalizing on the utility of biomarkers in the R&D programs in Alzheimer's disease, asthma, and type 2 diabetes.

"With the advances in biomarker research and in improved diagnostic imaging capabilities, the most notable impact of biomarker-involved drug development, outside of oncology, will be in central nervous system disorders," said Decision Resources Analyst Prachi Vora, M.P.H. "The incorporation of biomarker pathology in the inclusion criteria for a trial of Eli Lilly's solanezumab, an emerging therapy in Alzheimer's disease, is a key step toward mainstreaming biomarkers in CNS therapies."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
3. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
4. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
5. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
6. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
7. NIH funds research to identify Parkinsons biomarkers
8. New AAN/ALS Association Clinical Fellow Will Pursue Immune Biomarkers
9. Epigenetic biomarkers may predict if a specific diet and exercise regimen will work
10. Novel biomarkers improve diagnosis in rheumatoid arthritis
11. Biomarkers Market: Epigenetic & MicroRNA Biomarkers Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
Breaking Biology Technology: